(NASDAQ: ANTX) An2 Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
An2 Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ANTX's revenue for 2026 to be $2,162,203,052, with the lowest ANTX revenue forecast at $2,162,203,052, and the highest ANTX revenue forecast at $2,162,203,052.
In 2027, ANTX is forecast to generate $6,453,893,565 in revenue, with the lowest revenue forecast at $6,453,893,565 and the highest revenue forecast at $6,453,893,565.